期刊文献+

胰腺癌的CT增强与病理分级、瘤体血管生成的相关性研究 被引量:4

The correlative study of CT enhancement and histopathological grades, intratumoral angiogenesis in pancreatic carcinoma
暂未订购
导出
摘要 目的探讨胰腺癌的胰实质期CT增强与病理分级、瘤体实质细胞处的微血管密度(microvessel den-sity,MVD)、血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的相关性。方法选择经手术切除的胰腺癌患者30例,手术前均行CT增强扫描,观察胰腺癌胰实质期强化程度和形式;并对其手术标本行HE染色和免疫组化标记,对胰腺癌的CT强化状况、病理级别、瘤体实质细胞处的MVD和VEGF的表达行相关性分析。结果胰腺癌CT胰实质期瘤体强化程度、形式和其恶性度高低呈显著负相关(r=0.733,t=5.708,P<0.001),和瘤体实质细胞处MVD计数显著负相关(r=0.778,t=6.551,P<0.001);胰腺癌的病理分级和瘤体实质细胞处MVD计数正相关(r=0.437,t=7.574,P<0.05),而与VEGF表达无关(r=-0.240,t=-1.306,P>0.05)。VEGF阳性表达组MVD为57.7±11.1,VEGF阴性表达组MVD为44.6±12.2,两者差异有统计学意义(t=3.018,P<0.05)。结论胰腺癌CT胰实质期增强程度高低能反映肿瘤的恶性程度及瘤体实质细胞处MVD计数。胰腺癌的恶性度高低、VEGF表达均与MVD计数密切相关。 Objective To summarize the clinical feature and the surgical experience of primarily gallbladder carcinoma(PGC),evaluate the prognosis of PGC with different surgical treatment and the factors influencing the prognosis of PGC.Methods The clinic data of 103 patients with gallbladder cancers were analyzed retrospectively to reveal the relationship among of the stage of tumor,surgical modes and prognostic factors.Results One hundred and three patients were followed-up.The mean survival time was(19.6±18.4) months,the 1,3 and 5-year survival rate were 55.0%,25.0% and 8.0%.The 1,3 and 5-year survival rate were 81.0%,42.0% and 19.0% in radical resection group,significantly higer than that in palliative operation group and laparotomy biopsy group(P0.05).The mean survival time was(16.17±3.67)months in extended radical resection group,which was longer than that in the palliative operation group(9.22±1.125)months(P0.05).Multivariate analysis revealed that tumor,node,metastases stage and therapeutic interventions were independent prognostic factors for gallbladder cancer.Conclusion PGC is difficult to diagnose in early stage because it has no typical symptoms.The key point to improve the prognosis is diagnose early and had radical resection.We should do cholecystectomy in patient with high risk of PGC,or regular follow-up if the patient refused operation.We should give individual and active treatment to advanced PGC patients,the radical resection or the extended radical resection is effective way to improve the prognosis.
出处 《肝胆胰外科杂志》 CAS 2010年第5期384-388,共5页 Journal of Hepatopancreatobiliary Surgery
基金 温州市科技局科技计划项目(Y2005A096)
关键词 胰腺肿瘤 病理学 微血管密度 血管内皮生长因子 体层摄影术 X线计算机 primary gallbladder carcinoma diagnosis treatment radical resection
  • 相关文献

参考文献9

  • 1Yi CA,Lee KS,Kim EA,et al.Solitary pulmonary nodules:dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density[J].Radiology,2004,233(1):191-199.
  • 2Weidner N.Tumour vascularity and proliferation:clear evidence of a close relationship[J].J Pathol,1999,189(3):297-299.
  • 3Mattern J,Koomagi B,Volm M.Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumonr cell proliferation in human epidermoid lung carcinoma[J].Br J Cancer,1996,73(6):931-934.
  • 4Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J Med,1971,285(22):1182-1186.
  • 5Linder S,Blasjo M,von-Rosen A,et al.Pattern of disbution and prognostic value of angiogenosis in pancreatic duct carcinoma:a semiquantitative immunohistochemical study of 45 patients[J].Pancrens,2001,22(3):240-247.
  • 6Miles KA.Tumour angiogenesis and its relation to contrast enhancement on computed tomography:a review[J].Eur J Radiol,1999,30(3):198-205.
  • 7Knopp WV,Weiss E,Sinn HP,et al.Pathophysiologic basis of contrast enhancement in breast tumor[J].J Magn Reson Imaging,1999,10(3):260-266.
  • 8陈建峰.HIF-1α、VEGF在胰腺癌组织中的表达及临床意义[J].肝胆胰外科杂志,2008,20(5):343-346. 被引量:7
  • 9章福彬,朱斌,邵成浩.胰腺导管癌组织中VEGF表达和肿瘤微血管计数的临床意义[J].解放军医学杂志,2005,30(2):159-161. 被引量:3

二级参考文献19

  • 1Weidner N. Intratumor microvessel density as a prognostic factor in canaer. Am J Pathol,1995,147(1):9
  • 2Folkman J. Tumor angiogenesis: Therapeutic implication. N Engl J Med,1971,285:1182
  • 3Kuehn R, Lelkes PI, Bloechle C et al. Angiongesis,angiogenic growth factor, and cell adesion molecules are upreglatied in chronic pancreatic diseases: angiogenesis in chronic pancreatitis and in pancreatic cancer. Pancreas,1998,18:96
  • 4Itakura J, Ishiwata T, Shen B et al. Vessel counts and vascular lendothelial growth factor expression in pancreatic carcinoma. Eur J Cancer,1998,34:337
  • 5Seo Y, Baba H, Fukuda T et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer, 2000,88:2239
  • 6Ikeda N, Adachi M, Taki T et al. Prognostic significance of angiogenesis in human pancreatic cancer. Bri J Cancer,1999,79(9-10):1553
  • 7Mendel DB, Laird AD, Smolich BD et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des,2000,15(1):29
  • 8Fong TA, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor(Flk-1/KDR)that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res, 1999, 59(1):99
  • 9Folkman J. Tumor angiogenesis: therapeutic implication[J]. N Engl J Med, 1971,285(21): 1182.
  • 10Jiang H, Semenza GL, Bauer C, et al. Hypoxia-indueible factor-1 level vary exponentially over a physiologically relevant range of O2 tense[J]. Am J Physiol, 1996,271 (4 pt1): 1172- 1180.

共引文献8

同被引文献41

  • 1王中秋,黎介寿,卢光明,张新华.胰腺癌的CT增强和瘤体微血管密度及病理分级的相关性研究[J].中华医学杂志,2003,83(21):1882-1886. 被引量:29
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics [J]. Ca Cancer J Clin,2011,61(2):69-90.
  • 3Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets [J]. Nat Rev Gastroenterol Hepatol,2009,6(7):412- 422,.
  • 4Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer [J]. J Surg Res,2008,149(2):319- 328.
  • 5Weidner N. Tumour vascularity and proliferation: clear evidence of a close relationship [J]. J Pathol,1999,189(3):297-299.
  • 6Squadroni M, Fazio N. Chemotherapy in pancreatic adenocareinoma [J]. Eur Rev Med Pharmacol Sci,2010,14(4):386-394.
  • 7陈杰,李甘地,主编.病理学[M].第一版.北京:人民卫生出版社,2009,304-306.
  • 8Akisik MF, Sandrasegaran K, Bn G, et al. Pancreatic cancer:utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy[J]. Radiology, 2010,256(2): 441-449.
  • 9Rosenkrantz AB, Oei M, Babb JS, et al. Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproduc ibi I i ty compared with 1.5 Tesla[J]. Magnetic Resonance imaging, 2011, 33(1): 128- 135.
  • 10Park HS, Lee JM, Choi HK, et al. Preoperative eva luat ion of pancreatic cancer: comparison of gadolinium- enhanced dynamic MRI with MR cholangiopancreatography versus MDCT [J]. J Magn Reson Imaging, 2009, 30 (3) : 586-595.

引证文献4

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部